2025-09-28 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the provided data.  I'll follow your instructions, providing a summary in English, focusing on key numbers first, then adding analysis.

**Report: Recursion Pharmaceuticals Inc (RXRX) Analysis**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -34.75%
*   **VOO Cumulative Return:** 28.48%
*   **Absolute Divergence:** -54.6% (RXRX significantly underperformed the S&P 500)
*   **Relative Divergence:** 11.9% (The current divergence is near the lower end of its historical range).

**Analysis of Alpha/Beta:**

The following table summarizes the risk-adjusted performance metrics:

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2021-2023  | 10.0%  | 81.2% | -4.0%   | 0.0    | 4.3    |
| 2022-2024  | -10.0% | 81.2% | -22.0%  | -0.0   | 3.0    |
| 2023-2025  | 3.0%   | 79.0% | -32.0%  | -0.1   | 2.1    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) varies significantly across different periods, indicating volatility.
*   **MDD:** High Maximum Drawdown (MDD) values (around 80%) suggest substantial risk and price declines during the observed periods.
*   **Alpha:** Negative Alpha values consistently indicate underperformance relative to the benchmark.
*   **Beta:** Beta values close to zero suggest that RXRX's price movements are not strongly correlated with the overall market (S&P 500).
*   **Cap(B):** Decreasing Market Cap over time shows a decrease from 4.3 billion to 2.1 billion

**2. Recent Price Action**

*   **Current Price:** $4.72
*   **Previous Close:** $4.63
*   **Change:** +1.94% (Positive change from previous close)
*   **5-day Moving Average:** 4.839
*   **20-day Moving Average:** 4.7482
*   **60-day Moving Average:** 5.2681

**Analysis:** The stock price is currently below both the 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend. However, the recent positive change suggests a possible short-term rebound.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 53.14 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.4912 (Positive, but relatively small, suggesting potential upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **20-day Relative Divergence Change:** +0.7 (Short-term upward trend in relative performance)
*   **Expected Return:** -106.1% (Significant underperformance vs. S&P 500 expected over a 2+ year investment horizon)

**Analysis:**

*   The MRI suggests a generally favorable market environment for investment.
*   The recent price increase of 1.94% is significant and may signal a short-term upward trend.
*   The extremely negative expected return is a major red flag, indicating the model predicts substantial underperformance compared to the S&P 500 in the long term.

**4. Recent News & Significant Events**

*   **[2025-09-27]**  Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
*   **[2025-09-25]**  Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce
*   **[2025-09-22]**  Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
*   **[2025-09-21]**  Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances
*   **[2025-09-15]**  Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
*   **[2025-09-15]**  Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8

**Analysis:**

The news is mixed. Some articles discuss short squeeze potential and AI advantages, while others point to potential "dead cat bounce" scenarios. The milestone payment is a positive development. The "Stock Sinks As Market Gains" headline is concerning, indicating underperformance. The Needham analyst maintaining a "Buy" rating with a $8 target provides some positive counterpoint, but analyst ratings should be viewed critically.

**4-2. Analyst Opinions**

*   **Consensus:**  None
*   **Mean Rating:** Not Available
*   **Number of Opinions:** 6
*   **Target Price:**
    *   Average: $6.47
    *   High: $10.00
    *   Low: $3.00

**Analysis:** The analyst target price range is wide ($3.00 - $10.00), indicating considerable disagreement among analysts regarding the company's potential.  The average target price is higher than the current price, suggesting potential upside according to analysts, but the lack of consensus and recent rating changes being unavailable make this less reliable.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출    |
|--------------|-------|---------|
| 2025-08-05   | -0.41 | 0.02 B$ |
| 2025-05-05   | -0.5  | 0.01 B$ |
| 2024-11-06   | -0.34 | 0.03 B$ |
| 2024-08-08   | -0.4  | 0.01 B$ |
| 2025-08-05   | -0.4  | 0.01 B$ |

**Analysis:**

*   The company consistently reports negative Earnings Per Share (EPS), indicating a lack of profitability.
*   Revenue fluctuates but remains relatively low.  This suggests the company is still in a growth phase and heavily reliant on funding.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $0.92B    | -18.70%  |
| 2025-03-31 | $0.93B    | -21.68%  |
| 2024-12-31 | $1.03B    | -17.29%  |
| 2024-09-30 | $0.52B    | -18.27%  |
| 2024-06-30 | $0.58B    | -16.69%  |

**Analysis:**

*   **Revenue:** Revenue is inconsistent.
*   **Profit Margin:** Profit margins are volatile, with some quarters showing positive margins but others showing significant losses. The negative profit margins indicate that the company is spending significantly more than it is earning.
*   **Equity:** Equity has fluctuated, decreasing more recently.
*   **ROE:** Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profits from shareholders' investments.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) presents a mixed investment picture.

*   **Negative Factors:**  The company is significantly underperforming the S&P 500. The expected return is highly negative. Earnings and profitability are poor. High Maximum Drawdown indicates risk.
*   **Positive Factors:**  Recent news indicates a potential short squeeze. The Market Risk Indicator is positive.  Analyst price targets suggest potential upside (though with significant disagreement). Recent price action shows a slight rebound.

**Conclusion:**

Based on the data provided, Recursion Pharmaceuticals appears to be a **high-risk, speculative investment**. The company's long-term underperformance, lack of profitability, and negative expected return raise significant concerns. While there are some potential positive catalysts (short squeeze, AI advancements), they are not enough to outweigh the fundamental weaknesses. A more in-depth investigation into the company's pipeline, cash runway, and AI technology is recommended before considering an investment. The substantial difference between the current stock price and the high analyst target price ($10) is particularly concerning.
